Rezolute (RZLT) Receivables - Other (2011 - 2023)

Rezolute (RZLT) posted Receivables - Other of $400000.0 for Q3 2023, up 33.33% sequentially from $300000.0 in Q2 2023.

Analysis

Rezolute (RZLT) Receivables - Other (2011 - 2023) Analysis & Trends

Rezolute has reported Receivables - Other for 4 years, with the latest figure at $400000.0 in Q3 2023.

Quarterly Receivables - Other changed N/A year-over-year to $400000.0 in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $400000.0 (changed N/A YoY) and the FY2023 annual result came in at $300000.0, changed N/A from the prior year.
Receivables - Other climbed to $400000.0 in Q3 2023 per RZLT's latest filing, from $300000.0 in the prior quarter.
Over five years, Receivables - Other peaked at $400000.0 in Q3 2023 and troughed at $247000.0 in Q3 2019.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn
8	Royalty Pharma	28.45 Bn	27.61 Bn	-
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn
10	Rezolute	477.02 Mn	477.02 Mn	-

Historic Data

Download Data